Overexpression of the p53 protein in tumour cells can be explained by mutation in the p53 gene or complex formation of wild-type p53 protein with, for example, oncogene products causing a prolonged half-life of the p53 protein (Finlay, 1993; Oliner et al., 1993; Rubio et al., 1993) . In squamous cell carcinoma of the head and neck (SCCHN) p53 mutations are frequent and most often found in exons 5-8, which are parts of the conserved regions of the gene (Somers et al., 1992; Caamano et al., 1993) . Antibodies against p53 suitable for immunohistochemical detection in formalin-fixed and paraffin-embedded material are not able to distinguish between wild-type and mutant forms of the protein, and therefore no conclusions about mutation frequency can be drawn from immunohistochemical analysis of p53 expression. Recent studies of large-cell lymphomas and astrocytomas have pointed out a discrepancy between immunoreactivity for p53 and presence of mutations in the p53 gene (Cesarman et al., 1993; Rubio et al., 1993) , whereas studies of oesopjhageal and bladder cancer indicated a good correlation (Esrig et al., 1993; Wagata et al., 1993) . In oesophageal cancer detectable levels of p53 protein are closely correlated with the occurrence of missense mutations (Bennett et al., 1991) .
A convenient technique for studies of gene mutations is polymerase chain reaction (PCR) in combination with singlestrand conformation polymorphism (SSCP) analysis of the PCR product (Orita et al., 1991) . With the SSCP analysis up to 95% of all mutations can be detected, even with an admixture of normal cells of up to 85-90% (Michaud et al., 1992; Wu et al., 1993) . Since various mutations alter the properties of the protein differently (Finlay, 1993) , the site of p53 mutation is supposed to be of biological and clinical significance. More than 90% of the mutations in the p53 gene in general are missense mutations, causing a change in an amino acid and a probable increase in stability of the protein (Harris, 1993) . In a study of preinvasive and invasive SCCHN the frequency of missense mutations was 72% of all mutations found (Boyle et al., 1993) .
In squamous cell carcinoma in oesophagus nonsense as well as splice site mutations of the p53 gene have been reported (Audrezet et al., 1993; Huang et al., 1993; Wagata et al., 1993) . A nonsense mutation causes formation of a truncated protein usually unreactive with antibodies (Chen et al., 1994) . Splice site mutations have rarely been found in the p53 gene, but a hereditary splice site mutation in a family with breast and ovarian cancer has been reported causing loss of one exon owing to disruption of the splice acceptor site (Jolly et al., 1994) .
The functional and clinical importance of p53 expression and p53 mutation sites are under study in several tumour types. In hepatocellular carcinomas p53 protein and mRNA expression were found to be possible prognostic factors (Hsu et al., 1993) . A significant association between p53 mutations and high proliferative activity judged by Ki67 antigen positivity has been described in breast carcinoma (Marchetti et al., 1993 ), a tumour type in which p53 mutation has been suggested as an important prognostic indicator (Thorlacius et al., 1993) .
In a recent immunohistochemical study of p53 expression in SCCHN, no association between p53 deregulation and cell proliferation was found (Nylander et al., 1995) . However, since none of the three antibodies used could distinguish between wild-type and mutated protein, no conclusion could be drawn about mutation status versus cell proliferation. In the present study mutations in the p53 gene were determined in SCCHN using PCR and SSCP analysis and the relationship to immunohistochemical detection of p53 was evaluated. These data were further correlated to the expression of proliferating cell nuclear antigen (PCNA) and in vivo incorporation of the thymidine analogue iododeoxyuridine (IdUrd). November 1994 p53 in squamous cell carcinoma K Nylander et al a labelling index (LI) was calculated as described previously (Nylander et al., 1994) . The immunohistochemical evaluation and calculation of LI was performed by one of the authors (KN). Control calculations of LI showed a mean difference in intra-observer variation of 1.43% (range 5-10%), which was not statistically significant.
Materials and methods

Materials
Extraction of DNA from paraffin-embedded samples On paraffin-embedded blocks of SCCHN as much normal tissue as possible was scraped off with a scalpel. Depending on the size of the tumour, two or three 10-gLm sections were cut from each sample. DNA was extracted according to Shibata (1992) . In brief, sections were dewaxed in a series of xylene and ethanol and dried in a Speedvac (Savant Speedvac Plus, SC 1 A). Extraction buffer consisting of 100 mM Tris-HCI and 1 mM EDTA, pH 8.0, was added together with proteinase K at a concentration of 400 jig ml-'. Samples were incubated overnight at 37°C, and the following day boiled for 7 min and centrifuged, whereafter DNA was found in the supernatant.
Primers
Exons 4-9 of the p53 gene were amplified from each tumour using the following primers. For exons 5-9 see Gaidano et al. (1991) , and for exon 4:
P4-5 5'-TGCTCTTTTCACCCATCTAC-3' and P4-3 5'ATTGAAGTCTCATGGAAGCC-3' All primers were obtained from Scandinavian Gene Synthesis (K6ping, Sweden 
Results
Immunohistochemistry Twenty-one of the 33 tumours (64%) showed a distinct nuclear staining with the p53 antibody D07, with a median LI of 48% (range 11-85%). All tumours were positively stained with the antibodies against PCNA and IdUrd. Median LI for PCNA was 61% (range 23-90%) and for IdUrd 11% (range 3-40%) (Nylander et al., 1995) . PCR and SSCP analysis Amplification of exons 5-8 was accomplished in 95% of the reactions, and of exon 4 in 70% of the tumours. Sixteen mutations were found in 13 of the 33 tumours (39%). Ten of these mutations were demonstrated in 7 of the 21 p53-immunopositive tumours, meaning that 33% of the immunopositive and 50% of the immunonegative tumours (6 out of 12) were mutated as judged by the SSCP analysis. Two of the immunopositive tumours showed more than one mutation: one tumour had mutations in exons 5, 6 and 7 and the other tumour had mutations in exons 5 and 8 (Table  I) .
Twelve of the 16 mutations (75%) were located in exons 5, 7 and 8 encoding for parts of the five evolutionarily conserved p53 domains. Exon 5 mutations (four cases) were restricted to the immunopositive tumours. The remaining mutations were found in exon 6.
Since 6 of the 12 immunohistochemically negative tumours were shown to be mutated by PCR/SSCP (Figure 1 ), these cases were further studied by sequence analysis in order to determine the type of mutation in each case.
Sequence analysis All data for the sequenced samples are shown in Table I and Figure 2 .
Four of the tumours showed frameshift deletions. In one of these tumours, 14 bases in exon 8 were missing, and in another tumour two deletions and a combination of these were demonstrated to be distributed in different bacterial clones (Table I) , all causing formation of stop codons. A fifth tumour showed transversion of G->T, turning the mutated codon into a stop codon. The last tumour showed a splice site mutation in which the last base (g) in the splice acceptor site of intron 5 was transversed to a t. Theoretically this means inhibition of normal splicing (Lewin, 1990) causing omission of exon 6 in the mRNA. Because of this omission, a frameshift occurs, introducing a stop codon in exon 7. Unfortunately, no further tissue was available for RNA analysis.
Comparison of immunohistochemical and mutation data for pS3 with LI/PCNA and LI/IdUrd When comparing mutated with non-mutated tumours and immunopositive with immunonegative tumours no difference was found in LI/PCNA or in LI/IdUrd. (Table II) . In the present study mutations in the p53 gene were compared with immunohistochemical p53 protein expression in the same tumours. Immunopositivity was found in 64%, which is in the range found in earlier studies of SCCHN (Bennett et al., 1991; Field et al., 1991; Caamano et al., 1993) . A discrepancy existed concerning immunoreactivity and PCR-SSCP results with 39% of p53 mutated cases evenly distributed between immunopositive and immunonegative tumours. Similar data have been published for largecell lymphomas, astrocytomas and different cell lines (Wynford-Thomas, 1992; Cesarman et al., 1993; Rubio et al., 1993) . One explanation for this discrepancy could be that immunopositive but SSCP-negative tumours had mutations outside the exons studied (exons 4-9), leading to a prolonged p53 protein half-life. However, only a small percentage of mutations in SCCHN has been found outside exons 5-8 (Boyle et al., 1993) . A more probable explanation is that these tumours harboured excessive amounts of wild-type p53 retained by binding to other proteins (Finlay, 1993; Rubio et al., 1993) . The finding that all tumours with mutation in exon 5 were immunopositive could be explained by the fact that different mutations in the p53 gene alter properties of the protein differently, and mutation in exon 5 causes an approximate 5-to 12-fold increase in protein half-life compared with the wild-type p53 protein (Finlay, 1993) .
To enable detection of mutations, tumour tissue should constitute at least 10-15% of the total tissue sample (Wu et al., 1993) . In our material most of the adjacent normal tissue was removed before preparation of DNA, in order to reduce the risk of concealing tumour tissue. Using the SSCP technique, up to 95% of all mutations are found, which is another factor to take into account in the evaluation (Michaud et al., 1992) .
Missense mutations in the p53 gene cause an increase in protein stability, and it is logical that no such mutation was found among the immunonegative tumours. Instead these tumours contained four cases with deletions which, in accordance with earlier findings in immunonegative tumours (Chen et al., 1994) , caused frameshifts and formation of stop codons. These data also explain the discrepancy between immunonegativity and presence of mutations, since the mutations found resulted in a truncated p53 protein unreactive with the antibody used. It cannot be excluded that some of the immunopositive tumours also had mutations causing frameshifts and formation of stop codons and that the positive staining reaction was due to the presence of wild-type p53 protein. Considering data from other studies of p53 gene mutations in human cancers, nonsense and frameshift mutations, however, constitute only 5.5% of all p53 mutations studied (Levine et al., 1994).
A case with splice site mutation, to our knowledge only reported once before in SCCHN (Boyle et al., 1993) (Mack et al., 1993) . The opposite has been found in a human glioblastoma cell line, in which induction of wild-type p53 was accompanied by a down-regulation in PCNA expression (Mercer et al., 1991) . In the present study no obvious connection between PCNA expression and p53 mutations was found, and an effect of the p53 protein on PCNA regulation cannot be excluded. The reliability of PCNA as a cell proliferation marker has lately been questioned, since PCNA-positive cells have been observed in areas with no obvious cell proliferation (McCormick and Hall, 1992) .
In vivo labelling with the thymidine analogue IdUrd can give an indication of the 'true' tumour cell proliferation since it is incorporated in cells actively replicating DNA. The fact that no difference in LI/IdUrd was found between p53 mutated and non-mutated tumours indicated that p53 did not exert a measurable effect on tumour cell proliferation.
The clinical importance of mutations in the p53 gene in SCCHN remains to be explained (Frebourg et al., 1993) . It is well known that carcinogens affect the mutational pattern in the p53 gene (Habuchi et al., 1993; Perwez Hussain et al., 1994) and in SCCHN heavy smoking and drinking have been found to correlate to overexpression of the p53 protein (Langdon and Partridge, 1992) , but no thorough analysis of epidemiological factors and p53 mutation spectrum has been performed. We have now initiated a retrospective study focused on the relationship between different exposure factors and p53 gene mutations.
